/
Capricor Therapeutics, Inc. is a biotechnology company focused on the development and potential commercialization of cell and exosome-based therapeutics for the treatment of Duchenne muscular dystrophy ( DMD ), a rare genetic disorder characterized by progressive muscle degeneration and premature death, as well as other diseases with significant unmet medical need. Since our inception, we have …
Revenue declined 100.0% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -$73M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$0.00
▼ -100.0% YoY
Net Income (TTM)
-$115M
▼ -159.6% YoY
Op. Margin
—
ROIC
-46.32%
▲ +2.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$100M
▼ -76.7% YoY
Op. Cash Flow (TTM)
-$93M
▼ -74.5% YoY
Net Debt
-$264M
Net Cash Position
Cash & Equiv.
$279M
Continue Research